These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28256020)

  • 1. Left atrial anatomy and patient-related factors associated with adverse outcomes with the watchman device-a real world experience.
    Murarka S; Lazkani M; Moualla S; Verma DR; Pershad A
    J Interv Cardiol; 2017 Apr; 30(2):163-169. PubMed ID: 28256020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience.
    Price MJ; Reddy VY; Valderrábano M; Halperin JL; Gibson DN; Gordon N; Huber KC; Holmes DR
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1925-1932. PubMed ID: 26627989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial experience with the WATCHMAN™ left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry.
    Bonnet G; Salaun E; Pankert M; Cuisset T; Bonnet JL
    Arch Cardiovasc Dis; 2016 Dec; 109(12):689-695. PubMed ID: 27594651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.
    Reddy VY; Doshi SK; Kar S; Gibson DN; Price MJ; Huber K; Horton RP; Buchbinder M; Neuzil P; Gordon NT; Holmes DR;
    J Am Coll Cardiol; 2017 Dec; 70(24):2964-2975. PubMed ID: 29103847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous Left Atrial Appendage Closure with WATCHMAN™ device: peri-procedural and mid-term outcomes from the TRAPS Registry.
    Mazzone P; D'Angelo G; Regazzoli D; Molon G; Senatore G; Saccà S; Canali G; Amellone C; Turri R; Bella PD
    J Interv Card Electrophysiol; 2018 Jun; 52(1):47-52. PubMed ID: 29525913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Early (1-Week) Outcomes Following Left Atrial Appendage Closure With Amplatzer Devices.
    Koskinas KC; Shakir S; Fankhauser M; Nietlispach F; Attinger-Toller A; Moschovitis A; Wenaweser P; Pilgrim T; Stortecky S; Praz F; Räber L; Windecker S; Meier B; Gloekler S
    JACC Cardiovasc Interv; 2016 Jul; 9(13):1374-83. PubMed ID: 27388826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.
    Friedman DJ; Du C; Wang Y; Agarwal V; Varosy PD; Masoudi FA; Holmes DR; Reddy VY; Price MJ; Curtis JP; Freeman JV
    JACC Cardiovasc Interv; 2022 May; 15(9):950-961. PubMed ID: 35512918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation.
    Onalan O; Crystal E
    Stroke; 2007 Feb; 38(2 Suppl):624-30. PubMed ID: 17261703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
    Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
    Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Device-Related Thrombus and Associated Clinical Outcomes With the WATCHMAN Left Atrial Appendage Closure Device for Embolic Protection in Patients With Atrial Fibrillation (from the PROTECT-AF Trial).
    Main ML; Fan D; Reddy VY; Holmes DR; Gordon NT; Coggins TR; House JA; Liao L; Rabineau D; Latus GG; Huber KC; Sievert H; Wright RF; Doshi SK; Douglas PS
    Am J Cardiol; 2016 Apr; 117(7):1127-34. PubMed ID: 26993976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Canadian Multicenter Experience With WATCHMAN for Percutaneous Left Atrial Appendage Closure.
    Saw J; Fahmy P; Azzalini L; Marquis JF; Hibbert B; Morillo C; Carrizo A; Ibrahim R
    J Cardiovasc Electrophysiol; 2017 Apr; 28(4):396-401. PubMed ID: 28128883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedural and Short-Term Results With the New Watchman FLX Left Atrial Appendage Occlusion Device.
    Cruz-González I; Korsholm K; Trejo-Velasco B; Thambo JB; Mazzone P; Rioufol G; Grygier M; Möbius-Winkler S; Betts T; Meincke F; Sandri M; Schmidt B; Schmitz T; Nielsen-Kudsk JE
    JACC Cardiovasc Interv; 2020 Dec; 13(23):2732-2741. PubMed ID: 33189641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety profiles of percutaneous left atrial appendage closure devices: An analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database from 2009 to 2016.
    Jazayeri MA; Vuddanda V; Turagam MK; Parikh V; Lavu M; Atkins D; Earnest M; Di Biase L; Natale A; Wilber D; Reddy YM; Lakkireddy DR
    J Cardiovasc Electrophysiol; 2018 Jan; 29(1):5-13. PubMed ID: 28988455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Results of Left Atrial Appendage Closure with Watchman Device in Patients with Atrial Fibrillation.
    Pheerawong P; Songmuang SB; Lertsuwunseri V; Satitthummanid S; Srimahachota S
    J Med Assoc Thai; 2015 Oct; 98(10):942-9. PubMed ID: 26638585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Left Atrial Appendage Closure With the Watchman Device: Long-Term Results Up to 5 Years.
    Wiebe J; Franke J; Lehn K; Hofmann I; Vaskelyte L; Bertog S; Sievert H
    JACC Cardiovasc Interv; 2015 Dec; 8(15):1915-1921. PubMed ID: 26738659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices.
    Price MJ; Friedman DJ; Du C; Wang Y; Lin Z; Curtis JP; Freeman JV
    JACC Cardiovasc Interv; 2022 Nov; 15(21):2115-2123. PubMed ID: 36357014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study.
    Fastner C; Behnes M; Sartorius B; Yildiz M; Mashayekhi K; El-Battrawy I; Lehmann R; Baumann S; Becher T; Borggrefe M; Akin I
    BMC Cardiovasc Disord; 2016 Jan; 16():25. PubMed ID: 26822890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Cerebrovascular Events After Left Atrial Appendage Occlusion.
    Freixa X; Llull L; Gafoor S; Cruz-Gonzalez I; Shakir S; Omran H; Berti S; Santoro G; Kefer J; Landmesser U; Nielsen-Kudsk JE; Kanagaratnam P; Nietlispach F; Gloekler S; Aminian A; Danna P; Rezzaghi M; Stock F; Stolcova M; Paiva L; Costa M; Millán X; Ibrahim R; Tichelbäcker T; Schillinger W; Park JW; Sievert H; Meier B; Tzikas A
    Am J Cardiol; 2016 Dec; 118(12):1836-1841. PubMed ID: 27745964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation: A Single-center, Prospective, Observational Study.
    Huang WP; Zhang YH; He L; Su X; Yang XW; Guo ZX
    Chin Med J (Engl); 2017 Feb; 130(4):434-438. PubMed ID: 28218217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.